<?xml version="1.0" encoding="UTF-8"?>
<p>Because of the highly permeable nature of naringenin, it is absorbed throughout the gastrointestinal tract, largely in the small intestine via passive diffusion [
 <xref rid="B156-plants-09-01784" ref-type="bibr">156</xref>]. The gastroprotective effect of naringenin may be attributed to its anti-inflammatory activities, which is primarily achieved through inhibition of activator protein-1 and NF-κB signaling and activation of P38 MAPK and ERK 5 [
 <xref rid="B157-plants-09-01784" ref-type="bibr">157</xref>]. Over time, IBDs are known to progress to more severe forms like ulcerative colitis [
 <xref rid="B156-plants-09-01784" ref-type="bibr">156</xref>] and Crohn’s disease (CD). In such cases, treatment with naringenin has revealed anti-ulcerogenic effects in the form of decline in tissue ulceration, inflammation, and necrosis of the colon [
 <xref rid="B158-plants-09-01784" ref-type="bibr">158</xref>]. In addition, beneficial effects of naringenin may also be accomplished through suppression of pro-inflammatory markers like iNOS, reduction of inflammatory cytokines, diminished TLR4 mRNA, and protein concentration in mucosa [
 <xref rid="B159-plants-09-01784" ref-type="bibr">159</xref>].
</p>
